UPDATED: J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
J&J and Legend have withdrawn an abstract assessing Carvykti against a rival CAR-T therapy from Gilead and Arcellx. The move comes as data is being presented on both Carvykti and the rival CAR-T therapy in the treatment of advanced multiple myeloma. It is unclear how the withdrawn abstract may have compared the two therapies, but new data is being presented on both treatments.